Buprenorphine and naloxone compared with methadone treatment in pregnancy. 2015

Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
Departments of Obstetrics and Gynecology and Pediatrics, University of North Carolina School of Medicine, and the Department of Maternal and Child Health, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

OBJECTIVE To compare neonatal abstinence syndrome prevalence and characteristics among neonates born to women prescribed buprenorphine and naloxone compared with methadone during pregnancy. METHODS Retrospective cohort analysis of mother-neonate dyads treated with either buprenorphine and naloxone or methadone during pregnancy. Primary neonatal outcomes included diagnosis of neonatal abstinence syndrome, neonatal abstinence syndrome peak scores, total amount of morphine used to treat neonatal abstinence syndrome (mg), and duration of treatment for neonatal abstinence syndrome (days). Secondary outcomes included head circumference, birth weight, length, preterm birth, neonatal intensive care unit admission, Apgar scores, and overall length of hospitalization. RESULTS From January 1, 2011, to November 30, 2013, we identified 62 mother-neonate dyads, 31 treated with methadone and 31 treated with buprenorphine and naloxone. Sixteen neonates (51.6%) in the methadone group were diagnosed with neonatal abstinence syndrome compared with eight (25.1%) in the buprenorphine and naloxone group (adjusted odds ratio 2.55, 95% confidence interval [CI] 1.31-4.98, P = .01). The buprenorphine and naloxone-exposed neonates had lower peak neonatal abstinence syndrome scores (9.0 ± 4.4 compared with 10.7 ± 3.7, multivariate-adjusted mean difference = -2.77, 95% CI -4.99 to -0.56, P = .02) and shorter overall hospitalization (5.6 ± 5.0 compared with 9.8 ± 7.4 days, multivariate-adjusted mean difference = -3.90, 95% CI, -7.13 to -0.67, P = .02). We found no other differences in primary or secondary outcomes. CONCLUSIONS In a cohort of pregnant patients treated with either methadone or buprenorphine and naloxone in pregnancy, newborns exposed to maternal buprenorphine and naloxone had less frequent neonatal abstinence syndrome. Additionally, neonates exposed to buprenorphine and naloxone had shorter overall hospitalization lengths.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008691 Methadone A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) Amidone,Biodone,Dolophine,Metadol,Metasedin,Methaddict,Methadone Hydrochloride,Methadose,Methex,Phenadone,Phymet,Physeptone,Pinadone,Symoron,Hydrochloride, Methadone
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D009293 Opioid-Related Disorders Disorders related to or resulting from abuse or misuse of OPIOIDS. Opiate Addiction,Opiate Dependence,Opioid Misuse,Opioid Use Disorder,Prescription Opioid Abuse,Prescription Opioid Misuse,Addiction, Opioid,Dependence, Opioid,Opiate Abuse,Opioid Abuse,Opioid Addiction,Opioid Dependence,Abuse, Opiate,Abuse, Opioid,Abuse, Prescription Opioid,Addiction, Opiate,Dependence, Opiate,Disorder, Opioid Use,Misuse, Opioid,Misuse, Prescription Opioid,Opiate Abuses,Opioid Abuse, Prescription,Opioid Abuses,Opioid Addictions,Opioid Dependences,Opioid Misuses,Opioid Related Disorders,Opioid Use Disorders,Opioid-Related Disorder,Prescription Opioid Abuses,Prescription Opioid Misuses
D009294 Narcotics Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. Analgesics, Narcotic,Narcotic Analgesics,Narcotic,Narcotic Effect,Narcotic Effects,Effect, Narcotic,Effects, Narcotic
D009357 Neonatal Abstinence Syndrome Fetal and neonatal addiction and withdrawal as a result of the mother's dependence on drugs during pregnancy. Withdrawal or abstinence symptoms develop shortly after birth. Symptoms exhibited are loud, high-pitched crying, sweating, yawning and gastrointestinal disturbances. Abstinence Syndrome, Neonatal,Neonatal Withdrawal Syndrome,Passive Addiction, Neonatal,Substance Withdrawal, Neonatal,Neonatal Substance Withdrawal,Abstinence Syndromes, Neonatal,Addiction, Neonatal Passive,Addictions, Neonatal Passive,Neonatal Abstinence Syndromes,Neonatal Passive Addiction,Neonatal Passive Addictions,Neonatal Substance Withdrawals,Neonatal Withdrawal Syndromes,Passive Addictions, Neonatal,Substance Withdrawals, Neonatal,Syndrome, Neonatal Abstinence,Syndrome, Neonatal Withdrawal,Syndromes, Neonatal Abstinence,Syndromes, Neonatal Withdrawal,Withdrawal Syndrome, Neonatal,Withdrawal Syndromes, Neonatal,Withdrawal, Neonatal Substance
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011248 Pregnancy Complications Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. Adverse Birth Outcomes,Complications, Pregnancy,Adverse Birth Outcome,Birth Outcome, Adverse,Complication, Pregnancy,Outcome, Adverse Birth,Pregnancy Complication
D002047 Buprenorphine A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. 6029-M,Buprenex,Buprenorphine Hydrochloride,Buprex,Prefin,RX-6029-M,Subutex,Temgesic,Temgésic,6029 M,6029M,Hydrochloride, Buprenorphine,RX 6029 M,RX6029M

Related Publications

Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
March 2023, Acta obstetricia et gynecologica Scandinavica,
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
March 2024, Obstetrics and gynecology,
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
January 2022, Substance use & misuse,
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
January 2014, Addiction (Abingdon, England),
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
December 2014, Journal of acquired immune deficiency syndromes (1999),
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
October 2005, Expert review of pharmacoeconomics & outcomes research,
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
June 1997, Biological psychiatry,
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
January 2013, Substance abuse : research and treatment,
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
January 2015, Journal of addiction medicine,
Samantha L Wiegand, and Elizabeth M Stringer, and Alison M Stuebe, and Hendree Jones, and Carl Seashore, and John Thorp
March 2023, The New England journal of medicine,
Copied contents to your clipboard!